Hemin Lee1, Yinzhu Jin1, Miin Roh2, Theodore N Tsacogianis1, Sangshin Park3, Nam-Kyong Choi4, Seoyoung C Kim5,6. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3-030, Boston, MA, 02120, USA. 2. Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA. 3. Graduate School of Urban Public Health, University of Seoul, Seoul, Republic of Korea. 4. Department of Health Convergence, Ewha Women's University, Seoul, Republic of Korea. 5. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3-030, Boston, MA, 02120, USA. SYKIM@bwh.harvard.edu. 6. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. SYKIM@bwh.harvard.edu.
Abstract
BACKGROUND AND OBJECTIVE: There is a relative lack of head-to-head comparisons of denosumab against other osteoporosis drugs on safety. We aimed to explore ocular outcomes in patients with osteoporosis initiating denosumab vs zoledronic acid. METHODS: We conducted a cohort study using claims data (2010-15) from two large US commercial insurance databases including patients with osteoporosis who were aged 50 years or older and initiators of denosumab or zoledronic acid. The primary outcomes were (1) receipt of cataract surgery and development of (2) wet age-related macular degeneration and (3) dry age-related macular degeneration within 365 days after initiation of denosumab vs zoledronic acid. Propensity score fine stratification and weighting were used to control for potential confounding, and we calculated the incidence rate and hazard ratio for each outcome in the cohorts. The estimates from the two databases were combined with a fixed-effects model meta-analysis. RESULTS: The study cohort included 50,821 denosumab and 67,471 zoledronic acid initiators. In the propensity score-weighted analysis, compared to zoledronic acid use, denosumab was associated with a modestly decreased risk of undergoing cataract surgery (hazard ratio 0.91; 95% confidence interval 0.85-0.98) but not with the risk of wet age-related macular degeneration (hazard ratio 1.29; 95% confidence interval 0.99-1.70) or dry age-related macular degeneration (hazard ratio 1.03; 95% confidence interval 0.98-1.09). CONCLUSIONS: In this large population-based cohort study of 118,292 patients with osteoporosis, initiation of denosumab was associated with a modestly decreased risk of cataract surgery vs zoledronic acid. The risk of age-related macular degeneration was similar between the two drugs.
BACKGROUND AND OBJECTIVE: There is a relative lack of head-to-head comparisons of denosumab against other osteoporosis drugs on safety. We aimed to explore ocular outcomes in patients with osteoporosis initiating denosumab vs zoledronic acid. METHODS: We conducted a cohort study using claims data (2010-15) from two large US commercial insurance databases including patients with osteoporosis who were aged 50 years or older and initiators of denosumab or zoledronic acid. The primary outcomes were (1) receipt of cataract surgery and development of (2) wet age-related macular degeneration and (3) dry age-related macular degeneration within 365 days after initiation of denosumab vs zoledronic acid. Propensity score fine stratification and weighting were used to control for potential confounding, and we calculated the incidence rate and hazard ratio for each outcome in the cohorts. The estimates from the two databases were combined with a fixed-effects model meta-analysis. RESULTS: The study cohort included 50,821 denosumab and 67,471 zoledronic acid initiators. In the propensity score-weighted analysis, compared to zoledronic acid use, denosumab was associated with a modestly decreased risk of undergoing cataract surgery (hazard ratio 0.91; 95% confidence interval 0.85-0.98) but not with the risk of wet age-related macular degeneration (hazard ratio 1.29; 95% confidence interval 0.99-1.70) or dry age-related macular degeneration (hazard ratio 1.03; 95% confidence interval 0.98-1.09). CONCLUSIONS: In this large population-based cohort study of 118,292 patients with osteoporosis, initiation of denosumab was associated with a modestly decreased risk of cataract surgery vs zoledronic acid. The risk of age-related macular degeneration was similar between the two drugs.
Authors: Nam-Kyong Choi; Daniel H Solomon; Theodore N Tsacogianis; Joan E Landon; Hong Ji Song; Seoyoung C Kim Journal: J Bone Miner Res Date: 2017-02-07 Impact factor: 6.741
Authors: D V Patel; M Bolland; Z Nisa; F Al-Abuwsi; M Singh; A Horne; I R Reid; C N J McGhee Journal: Osteoporos Int Date: 2014-09-04 Impact factor: 4.507
Authors: Michael Gnant; Georg Pfeiler; Günther G Steger; Daniel Egle; Richard Greil; Florian Fitzal; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger-Zeinitzer; Vesna Bjelic-Radisic; Raimund Jakesz; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Ruth Exner; Christian Fesl; Sophie Frantal; Christian F Singer Journal: Lancet Oncol Date: 2019-02-19 Impact factor: 41.316
Authors: Daxin Tang; Douglas Borchman; Marta C Yappert; Gijs F J M Vrensen; Vittorio Rasi Journal: Invest Ophthalmol Vis Sci Date: 2003-05 Impact factor: 4.799